TORONTO – Health Canada has granted approval for the first generic version of the well-known diabetes medication Ozempic, marking a significant development in the Canadian pharmaceutical market. The Canadian government department announced that Canada becomes the first G7 country to authorize a generic version of semaglutide, the active ingredient in Ozempic.
This generic formulation of the injectable medication is manufactured by Dr. Reddy's Laboratories, based in India, and is approved for use in the once-weekly treatment of Type 2 diabetes in adults. This approval comes as many Canadians who lack drug coverage have been waiting eagerly for a more affordable option, as Novo Nordisk's Ozempic can cost patients hundreds of dollars each month.
Health Canada highlighted the financial advantages of generic medications, stating that they can often be priced 45 to 90 percent lower than their brand-name counterparts. The cost-effectiveness of generic semaglutide is particularly important given the high price of Ozempic, making it inaccessible for some segments of the population.
While the medication is officially approved for diabetes treatment, it has also gained popularity for off-label use in weight loss, further driving demand for affordable alternatives. As part of its ongoing efforts, Health Canada is reviewing an additional eight submissions for generic semaglutide from other pharmaceutical companies, indicating potential for increased competition in the market.
The degree to which generic semaglutide will be less expensive than Ozempic will depend on the number of generic options that enter the market. According to Mina Tadrous, a pharmaceutical policy expert at the University of Toronto, initial pricing structure set by the pan-Canadian Pharmaceutical Alliance suggests that the first generic medication could be priced at 75 to 85 percent of the cost of Ozempic. Once a second generic product becomes available, prices for both generics are expected to drop to around 50 percent of the brand-name price. With three or more generic products on the market, the cost could decrease to about 35 percent of the original Ozempic price.
Earlier in March 2026, India's drug agency had already approved two generic versions of semaglutide produced by Dr. Reddy's Laboratories, after the expiration of Novo Nordisk's patent in that country. The specific generic version recently approved by Health Canada was submitted for review in early 2024, and the approval process adhered to the department's target timeline of six months. It is important to note that this timeline does not account for any additional data or information that Health Canada may have requested from the company during the evaluation process.
In its news release, Health Canada emphasized that the generic versions of semaglutide are complex synthetic products that are pharmaceutically equivalent to the brand-name biologic drug. The department conducted a thorough review to ensure that differences between the generic products and the original do not compromise safety, efficacy, or quality.
Overall, the availability of generic drugs in Canada is anticipated to have a positive impact, potentially leading to significant cost savings for patients and the healthcare system. This news represents a pivotal shift in the accessibility of treatments for those living with Type 2 diabetes in Canada, and it highlights the ongoing evolution and competition within the pharmaceutical industry.
